German outpatient PET (positron emission tomography) decision slammed
This article was originally published in Clinica
A recent decision by the German federal committee of doctors and sickness funds to exclude positron emission tomography (PET) from the catalogue of reimbursable procedures for outpatients has been strongly criticised by the German society for nuclear medicine (DGN). Each scan costs E800-1000 ($707-883) and the committee believes this is too expensive. It also claims that the outcome of a PET scan cannot positively influence a decision on what therapy is necessary. In addition to this, PET is still at the research stage, it says.
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.